Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Need For Biotech Generic Drugs Seen As Boon For China

This article was originally published in PharmAsia News

Executive Summary

Drug policy pressures on the United States could have an ancillary effect of making more Chinese drug firms bigger players in the world market, one expert believes. Dr. Jim Wei, a former senior reviewer for the U.S. FDA and now director of clinical pharmacology at the contract research organization Medpace, says the pressure on the United States to lower drug prices encourages foreign drug makers to enter the market for generic drugs. He said that situation is leading to an increase in the need for generic protein drugs, an area of biotech drugs where the legality of copying is hazy in the United States. As the demand rises, "Chinese manufacturers have the ability to produce such products," Wei says. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068540

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel